Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mgAccesswire • 03/08/23
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 03/01/23
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022Accesswire • 02/28/23
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023Accesswire • 02/22/23
Amphastar: Generating High Incremental Growth From Tidy Earnings ReinvestmentSeeking Alpha • 02/09/23
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare ConferenceAccesswire • 11/22/22
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare ConferenceAccesswire • 11/10/22
Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to DeclineZacks Investment Research • 10/31/22
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022Accesswire • 10/28/22
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare ConferenceAccesswire • 09/02/22
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled SyringesAccesswire • 08/16/22
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A StandstillInvestors Business Daily • 08/08/22
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022Accesswire • 08/08/22
Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And BeyondSeeking Alpha • 08/08/22
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022Accesswire • 08/01/22